SEL120-34A(SEL120), a clinical trial phase I CDK8 inhibitor, has been shown to downregulate phosphorylation level of STAT1 and STAT5 in AML cells lines [29]. The gene discussed is STAT1; the disease is acute myeloid leukemia.